food-safety · agriculture · manufacturing · family: the solution exists but nobody can afford it
brewed to perfection,too expensive to eat
Precision fermentation proteins cost too much to purify for food-industry margins
Problem statement
Precision fermentation — engineering microorganisms to produce specific food proteins (dairy, egg and collagen proteins, such as whey) identical to those found in animal products — faces a downstream processing cost barrier that prevents price parity with conventional dairy and egg proteins. Perfect Day ($840M raised, laid off 15% of its workforce, consumer brands sold off, sued by contract manufacturer Olon for $134M, most of it unpaid bills) demonstrated that beta-lactoglobulin (whey protein) can be produced under contract and commercialised in consumer products, but separating the protein from the rest of the fermentation broth is where much of the cost sits: downstream processing can account for over half of production costs in low-purity industrial enzyme production and up to 85% of costs in pharmaceutical biologics, and few to no downstream unit operations have been designed specifically for this industry. Scaling up to immense tank volumes will at best cut costs by 35–40%, where a many-fold reduction is needed to compete with commodity dairy or eggs.
Why this matters
Precision fermentation promises proteins identical to those found in animal products at what the AgroFOOD authors call a fraction of the environmental cost of conventional farming. By the late 2010s first movers such as Clara Foods, Geltor and Perfect Day had raised hundreds of millions of dollars to produce egg, dairy and collagen ingredients, and dozens of other startups followed. However, if costs cannot be brought down many-fold — not the 35–40% that larger tanks at best offer — precision-fermented proteins will remain limited to applications that command high prices or are used in small quantities rather than replacing bulk dairy and egg protein at commodity scale.
What’s been tried and why it hasn’t worked
Perfect Day had its beta-lactoglobulin produced by a contract manufacturer (CMO), Italian firm Olon, which spent six years making it and put €81M ($86M) into expanding and tailoring its plant to Perfect Day's specifications; the relationship ended in a $134M lawsuit — $112M in unpaid manufacturing fees, unreimbursed capital expenditure, raw material and other costs, plus damages — after Perfect Day allegedly stopped paying in August 2023 and, Olon says, planned to move production to cheaper plants in India. The fundamental issue is that separating the protein of interest from the rest of the fermentation broth is deceptively complex, and few to no downstream unit operations have been designed specifically for this industry. Scaling up to immense tank volumes will at best reduce costs by 35–40%, not the many-fold reduction needed. Increasing protein titer (grams per liter) in the bioreactor is still among the highest-return activities, but some experts believe titers of common workhorse strains such as P. pastoris and T. reesei are beginning to plateau. The broader precision fermentation industry faces the same challenge — leading scientists and technologists from industry and academia told the TechCrunch columnist that the economics of food-grade precision fermentation is nowhere near competing with commodity dairy or eggs.
What would unlock progress
Rethinking bioseparations — designing downstream unit operations for food-grade fermentation, where today few to none exist — could attack what the column describes as a large share of production cost. Continuous processing or perfusion culture could raise space-time yield, producing substantially more product in a shorter time in smaller production settings. Continued engineering of host organisms for higher protein titers remains a high-return activity, even as common workhorse strains may be approaching plateaus. A biorefinery mindset that valorizes high-volume waste streams — microbial biomass will be produced in colossal quantities as the sector industrializes — could improve the economics further. The AgroFOOD authors add that process design and techno-economic analysis should start right after proof-of-concept, rather than transferring lab-scale data to a larger scale and reacting to problems as they appear.
Entry points for student teams
A team could perform a detailed techno-economic analysis comparing downstream processing routes for a model food protein (beta-lactoglobulin), quantifying cost contributions of each unit operation and identifying the highest-impact cost reduction targets. An experimental team could test a single-step protein capture method (e.g., aqueous two-phase extraction, stimulus-responsive tags) and measure recovery yield, purity, and cost relative to conventional multi-step purification. Relevant disciplines: biochemical engineering, food science, bioprocess engineering, protein chemistry.
Genes
Structural cousins: stuck the same way, in other fields
Sources
AgroFOOD Industry Hi Tech, "The Ghost of Scale-Up in Precision Fermentation," 35(3), 2024, Green Queen, Anay Mridul, "Perfect Day Faces $134M Lawsuit by Manufacturing Partner for Breach of Contract & Unpaid Bills," April 16, 2024, TechCrunch, Blake Byrne, "Precision fermentation's capacity craze: Have we lost the plot?", April 24, 2023, accessed 2026-02-20 go to source 1 ↗ go to source 2 ↗ go to source 3 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
Perfect Day ($840M raised) is the best-documented case, but the downstream processing cost barrier is industry-wide: the TechCrunch column reports that leading scientists and technologists say the economics of food-grade precision fermentation is nowhere near competing with commodity dairy or eggs. Related: chemistry-synbio-commodity-molecule-cost-floor (overlapping fermentation cost-floor challenge for small molecules; this brief is specifically about protein purification, which has different bottlenecks — proteins require gentle processing to maintain functionality). Related: food-cultivated-meat-bioreactor-scaling (different approach to animal-free protein — cell culture vs. precision fermentation — with different technical bottlenecks). Domain gap value: adds to underrepresented food-safety and agriculture domains.
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against every source it names. All three were fetched in full on 2026-09-30, directly from their publishers: the AgroFOOD Industry Hi Tech article by Attaianese, Andreutti and Fenizia (https://digital.h5mag.com/agrofood_industry_hi_tech_35_3_2024/precision_fermentation_-_the_ghost_of_scale-up_in_precision_fermentation); the Green Queen report on the Olon lawsuit (https://www.greenqueen.com.hk/perfect-day-olon-lawsuit-contract-unpaid-bills-precision-fermentation/); and the TechCrunch column by Blake Byrne (https://techcrunch.com/2023/04/24/precision-fermentations-capacity-craze-have-we-lost-the-plot/), whose address the Source line had not carried and now does. (1) The Source line dated the Green Queen report 2023; the page says it was published April 16, 2024, and its full title is now copied from the page. (2) "Sued ... for $134M in unpaid bills" and "costs escalated to $134M in disputed bills": Green Queen says the $134M suit is $112M in unpaid manufacturing fees, unreimbursed capital expenditure, raw material and other costs, plus damages (the report gives the damages figure as $22M in one place and $32M in another, so no damages figure is used); the text now says so. (3) "Consumer business shuttered": Green Queen says Perfect Day sold its direct-to-consumer subsidiary, The Urgent Company, to Superlatus; the text now says the consumer brands were sold off. (4) "When production problems arose at Italian CMO Olon": no source describes production problems. Green Queen says Olon spent six years producing the protein, invested €81M ($86M) in its plant, and alleges that Perfect Day stopped paying in August 2023 and planned to move production to cheaper plants in India; the sentence now follows the report, and "outsourced large-scale fermentation" (no source says large-scale) now reads "had its beta-lactoglobulin produced by a contract manufacturer". (5) "Fungal hosts (Trichoderma reesei)" as Perfect Day's production host is not in any source (TechCrunch names T. reesei only as a common workhorse strain of the industry); removed. "At commercial scale" now reads "commercialised in consumer products", Green Queen's word for the protein Olon made for Perfect Day. (6) "Filtration, chromatography, and spray drying that accounts for 50–85% of total manufacturing cost": TechCrunch says downstream processing can account for over half of production costs in low-purity industrial enzyme production and up to 85% in pharmaceutical biologics, and names no unit operations; the text now gives those two figures with what they count, and the column's statement that few to no downstream unit operations have been designed for this industry. (7) "Even at maximum theoretical bioreactor optimization, downstream processing costs alone keep ... prices" and "scaling up bioreactor volume to 100,000+ liters reduces fermentation cost per gram by 35–40% but barely affects downstream processing costs, which scale more linearly with volume": TechCrunch says only that scaling up to immense tank volumes will at best reduce costs by 35% to 40% instead of the many-fold reduction needed; both sentences now say that. (8) Removed because no source contains them: animal agriculture as ~14.5% of global greenhouse gas emissions; EUR 120M raised in Europe in 2024 (3× 2023); New Culture, Formo and Every Company as examples; a needed 3–5× cost reduction (TechCrunch says "many-fold"); "~50–100 g/L at best" broth concentration; the list of unit operations with yield losses and energy costs; cell stress, misfolding and viscosity as titer limits (TechCrunch says some experts believe titers of common workhorse strains are beginning to plateau); and in the notes, Every Company's ~$175M raised, Remilk's acquisition by Danone in 2025, and Formo's casein. The examples now given (Clara Foods, Geltor, Perfect Day; egg, dairy and collagen ingredients) are TechCrunch's. (9) "No company has achieved cost parity" was softened to what TechCrunch reports: scientists and technologists told the columnist that the economics of food-grade precision fermentation is nowhere near competing with commodity dairy or eggs. (10) "Whey, casein, collagen, ovalbumin": no source names casein or ovalbumin; the text now says dairy, egg and collagen proteins, such as whey. (11) The "What Would Unlock Progress" section proposed engineered secretion systems, affinity or stimulus-responsive purification, and food-grade biomass hosts; none is in a source. It now follows the four areas the TechCrunch column names (rethinking bioseparations, continuous or perfusion processing, higher titers, a biorefinery mindset for waste streams such as microbial biomass) and the AgroFOOD authors' call for process design and techno-economic analysis to begin right after proof-of-concept. Confirmed in the sources and left as written: $840M total funding; the 15% layoff; Olon as an Italian contract manufacturer; the $134M suit; beta-lactoglobulin as the whey protein; precision fermentation as engineered microorganisms making proteins identical to those in animal products; downstream processing as a cost barrier to parity with dairy and egg proteins; premium applications versus commodity dairy and egg; the AgroFOOD citation (35(3), 2024) and the TechCrunch title and year. The entry points are proposals, not factual claims, and were left as written. Neither title changed. Genome tags untouched. A second reader went over the repairs on the same day, fetched all three sources again in full, found no original sentence that a source supported, and tightened four phrases that still said more than the sources do ("at commercial scale", "large-scale fermentation", "the largest cost block", "larger tanks alone offer") to the sources' own terms.